Emergency Preparedness and Response
Pillar III Goals and Highlights, 2012
Implement Changes to PAHPA: An MCMi legal/policy team analyzed the existing statutory framework for making medical countermeasures available in emergency circumstances. Based on their analysis, FDA developed proposals for changes to the Pandemic and All Hazards Preparedness Act (PAHPA). If the proposed changes are included during the reauthorization process, they will enhance clarity and flexibility for FDA's emergency use authorization (EUA) of medical countermeasures before a chemical, biological, radioactive, or nuclear event (or emerging disease threat). The proposed changes will support rapid deployment and pre-event planning and positioning of medical products. Once PAHPA has been reauthorized, FDA will begin the process of implementing those changes and keep you informed on this page.
Highlights (Events, Presentations, Accomplishments)
- March 2012, FDA-ASPR MOU: The purpose of the MOU is to promote collaboration and enhance knowledge and efficiency by providing for the sharing of information and expertise between the Federal Partners.
- March 15, 2012, Webinar and Slides on Recent Developments in FDA's Emergency Authority for Medical Countermeasures, from the Public Health Law Webinar Series.
- FDA is working with State and local authorities and responders to support preparedness and response capabilities at the state and community levels.